Citius Pharmaceuticals Inc Stock
Citius Pharmaceuticals Inc Stock price
Key metrics
| Market capitalization | $9.77m |
| Enterprise Value | $9.74m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 0.13 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-42.99m |
| Free Cash Flow (TTM) Free Cash Flow | $-23.55m |
| Cash position | $30.00k |
Is Citius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
Citius Pharmaceuticals Inc Stock Analysis
Analyst Opinions
3 Analysts have issued a Citius Pharmaceuticals Inc forecast:
Analyst Opinions
3 Analysts have issued a Citius Pharmaceuticals Inc forecast:
Financial data from Citius Pharmaceuticals Inc
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -43 -43 |
10%
10%
|
| Net Profit | -43 -43 |
15%
15%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Citius Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Citius Pharmaceuticals Inc Stock News
Company Profile
Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
| Head office | United States |
| CEO | Leonard Mazur |
| Employees | 23 |
| Founded | 2007 |
| Website | www.citiuspharma.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
